Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26099344 | 1.00 | PAX8 (0.42) | PAX8HCRTR2BRD4ALDH1A1RAB9A | |
| SCHEMBL26099322 | 0.78 | LMNA (0.40) | BRD4ALDH1A1KMT2APKMTSHR | |
| SCHEMBL26100676 | 0.78 | LMNA (0.40) | BRD4ALDH1A1KMT2APKMTSHR | |
| SCHEMBL26101121 | 0.75 | PSIP1 (0.40) | ALDH1A1KMT2AKDM1APKMKDM4E | |
| SCHEMBL26101120 | 0.75 | PSIP1 (0.40) | ALDH1A1KMT2AKDM1APKMKDM4E | |
| SCHEMBL26099362 | 0.75 | CA1 (0.36) | ALDH1A1KMT2AKDM1AKDM4EHPGD | |
| SCHEMBL23932441 | 0.74 | PAX8 (0.48) | PAX8BRD4ALDH1A1RAB9AKMT2A | |
| SCHEMBL30392546 | 0.72 | DRD2 (0.39) | ALDH1A1PKML3MBTL1DRD2 | |
| SCHEMBL30391091 | 0.72 | DRD2 (0.39) | ALDH1A1PKML3MBTL1DRD2 | |
| SCHEMBL26100695 | 0.72 | DRD2 (0.39) | ALDH1A1PKML3MBTL1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016864-B2 | LOX enzyme inhibiting methods and compositions | ANOVIA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230390299-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES INC (US) | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390299-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | LOX, LOXL1, LOXL2 | PAX8 4042/4885HCRTR2 856/4885BRD4 1577/4885 |
| US-12016864-B2 | LOX enzyme inhibiting methods and compositions | LOX, LOXL1, LOXL2 | PAX8 3021/4885HCRTR2 418/4885BRD4 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.